News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

pSivida Limited (PSD.AX) Release: Results From The Six-Month Interim Readout Of The Human PK Iluvien(TM) Study


10/1/2008 11:05:39 AM

BOSTON--(BUSINESS WIRE)--Drug delivery company, pSivida Corp. (NASDAQ: PSDV)(ASX: PVA)(FF: PV3), together with its licensing and development partner, Alimera Sciences, have today reported the interim six-month safety and efficacy results from the first human pharmacokinetici (PK) study of Medidur™ FA, which will be marketed under the trade name Iluvien™, if approved by the U.S. Food and Drug Administration.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES